

Dear Colleagues,

it is my great pleasure to announce the 15th Rostock Symposion for Tumor Immunology and Brain Tumor Research in Pediatrics. It will be performed completely virtual - in Corona times – however, I think, due to a lot of great contributors, the program is going to be fantastic !

All subjects ranging from immunology to brain tumor research, genetics, applied immunotherapy, and oncology, from clinical studies to basic science will be covered.

As in all our previous meetings, again a great number of reknown physicians and scientists will share with us their knowledge and experiences, including newest research data.

And of course, again, it will certainly be a very lively event, with much opportunity to communicate in a familiar surrounding – particularly in the very special evening event.

Although meeting in person will not be possible, there will be plenty of opportunities to come together - and I hope that all of us will learn a lot - and will have a lot of fun together.

Rostock, January 2021



C. F. Classen

Thank you to our Sponsors:

Novartis (Details following)

Grifols (Details following)

Medac (Details following)

Chugai (Details following)

GRIFOLS

medac
Hämatologie



NOVARTIS
ONCOLOGY

**Virtual access data will be
communicated upon request**

**Elektronische Zugangsdaten werden
auf Anfrage per Email mitgeteilt**


carl-friedrich.classen@med.uni-rostock.de
Tel. 0381 / 494 7255
Fax. 0381 / 494 7261

**Kinder- und Jugendklinik der
Universitätsmedizin Rostock**
Direktor Prof. Dr. J. Däbritz
Ernst-Heydemann-Str. 8
D - 18057 Rostock
AG Hirntumorforschung
Prof. Dr. med. Carl Friedrich Classen

Universität
Rostock  Traditio et Innovatio

 **Universitätsmedizin
Rostock**

**Kinder- und Jugendklinik
Universitätsmedizin Rostock**



**15th ROSTOCK SYMPOSION
for Tumor Immunology and Brain
Tumor Research in Pediatrics
Friday 19 and Sat. 20 Feb. 2021
Virtual Congress
– login data upon request**

PROGRAM

Friday 19. February 2021

9:00 Welcome: News on the immune system

Human basophilic granulocytes: their emerging role in autoimmunity and malignancy.

Almut Meyer-Bahlburg, Greifswald

Primary ciliary dyskinesia as differential diagnosis in recurrent chest infections.

Claudius Werner, Schwerin

Investigation of DNA damage response in peripheral blood lymphocytes by mass cytometry.

Kerstin Felgentreff, Ulm

Acute and chronic Graft-versus-Host-Disease after allogeneic hematopoietic stem cell transplantation impair B-cell reconstitution at different maturation stages.

Daniel Wolff, Regensburg

Heat inactivation of human serum destroys C1 inhibitor, promotes immune complex formation and improves human T cell function.

Matthias A. Fante, Regensburg

11:00 Coffee Break (30 min.)

11:30 What tells us the cell?

Single-cell RNA sequencing of paediatric and adult choroid plexus tumors.

Annarita Patrizi, Heidelberg

MicroRNA expression profiles of serum- and cell culture-derived Extracellular Vesicles from patients with malignancies.

Christian Scheiber, Ulm

The immunological side of PiCoP – Reactivity of peripheral blood lymphocytes from cancer patients.

Sandra Wagner, Rostock

Integrated biobanking: something new, something old and something borrowed.

Michael Linnebacher, Rostock

13:00 Lunch break (60 min.)

14:00 Understanding Cancer and new Therapies

From genetic predisposition to infection exposure in childhood leukemia

Julia Hauer, Dresden

Multiple facets of hereditary cancer susceptibility

Michaela Kuhlen, Augsburg

CAR T cells in pediatric oncology - progress beyond refractory leukemias

Claudia Rössig, Münster

Nivolumab and dinutuximab beta in refractory neuroblastoma

Karoline Ehlert, Greifswald

The RIST protocol in the treatment of Medulloblastoma

Anna Sarah Weber, Andrew Westhoff, Ulm

16:00 Coffee Break (30 min.)

16:30 Molecular News on Brain Tumors

Next generation molecular diagnostics in brain tumor neuropathology

Julia Lorenz, Markus J. Riemenschneider, Regensburg

Sp1 inhibitor mithramycin A suppresses the survival of patient-derived glioblastoma cell lines

Katharina del Moral Neujahr, Rostock

Combined treatment with ONC201/TIC10 and 2-deoxyglucose has a synergistic anti-proliferative activity in medulloblastoma in vitro

Georg Karpel-Massler, Ulm

19:30 Evening Event – Online Concert with Edith Piaf / Jacqueline Boulangier – and Come-Together

Saturday 20. February 2021:

9:00 Wake Up and Come Back: Novel Brain Tumor Treatment Strategies

Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged

Stefaan van Gool, Köln

Concomitant dexamethasone treatment and Tumor Treating Fields induced cell death in Glioblastoma.

Daniel Dubinski, Rostock

Therapeutic targeting of short-distance communication between Glioblastoma cells and their direct microenvironment

Hannah Strobel, Andrew Westhoff, Ulm

3D printing - Useful tool in oncology research?

Franziska Prehn, Rostock

11:00 Coffee Break (30 min.)

11:30 Learning Glioblastoma Treatment from Cellular Models

The potentially cytostatic effects of Temozolomide on Glioblastoma cells

Amina Hadzalic, Andrew Westhoff, Ulm

Susceptibility of Glioblastoma cell lines against short-term cytokine activated killer cells

Nora Schwingen, Marion Schneider, Ulm

Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models

Christin Rieß, Rostock

13:00 Fare Well